 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for CETN1 |
 Gene summary |
| Basic gene information | Gene symbol | CETN1 |
| Gene name | centrin, EF-hand protein, 1 | |
| Synonyms | CEN1|CETN | |
| Cytomap | UCSC genome browser: 18p11.32 | |
| Type of gene | protein-coding | |
| RefGenes | NM_004066.1, | |
| Description | EF-hand proteincalcium binding proteincaltractincentrin-1 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 603187 | |
| HGNC : HGNC | ||
| HPRD : 04425 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_CETN1 | |
| BioGPS: 1068 | ||
| Pathway | NCI Pathway Interaction Database: CETN1 | |
| KEGG: CETN1 | ||
| REACTOME: CETN1 | ||
| Pathway Commons: CETN1 | ||
| Context | iHOP: CETN1 | |
| ligand binding site mutation search in PubMed: CETN1 | ||
| UCL Cancer Institute: CETN1 | ||
| Assigned class in TissGDB* | A | |
| Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
| Reference showing the relevant tissue of CETN1 | Testis-specific murine centrin, Cetn1: genomic characterization and evidence for retroposition of a gene encoding a centrosome protein. Hart PE, Glantz JN, Orth JD, Poynter GM, Salisbury JL. Genomics. 1999 Sep 1;60(2):111-20. (pmid:10486202 ) go to article | |
| Description by TissGene annotations | TissgsKTS CNV gained TissGeneKTS | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for CETN1 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| Top |
| TissGene-miRNA for CETN1 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for CETN1 |
| TissGeneSNV for CETN1 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.E67K | SKCM | 2 |
| p.E148K | UCEC | 2 |
| p.D147N | SKCM | 2 |
| p.D116N | SKCM | 2 |
| p.A56D | LUAD | 2 |
| p.E156K | SKCM | 2 |
| p.E63K | SKCM | 2 |
| p.G44R | READ | 1 |
| p.Q31K | LUAD | 1 |
| p.R34W | READ | 1 |
| p.G119R | ESCA | 1 |
| p.E63K | LUSC | 1 |
| p.G119E | LUAD | 1 |
| p.E117X | THYM | 1 |
| p.K96N | BLCA | 1 |
| p.E160* | HNSC | 1 |
| p.P64T | LUAD | 1 |
| p.D150A | LGG | 1 |
| p.E63K | KIRP | 1 |
| p.D139N | SKCM | 1 |
| p.G46R | SKCM | 1 |
| p.V42L | ESCA | 1 |
| p.R164W | READ | 1 |
| p.R151W | HNSC | 1 |
| p.R58K | BLCA | 1 |
| p.S122L | UCEC | 1 |
| p.S122L | SKCM | 1 |
| p.K51N | UCEC | 1 |
| p.E68K | STAD | 1 |
| p.G119R | COAD | 1 |
| p.E99K | LUAD | 1 |
| p.E99K | UCEC | 1 |
| p.F62V | UCEC | 1 |
| p.E148K | SKCM | 1 |
| p.E105K | SKCM | 1 |
| p.D41N | HNSC | 1 |
| p.R17G | HNSC | 1 |
| p.D116G | STAD | 1 |
| p.E67Q | HNSC | 1 |
| p.D49Y | LUSC | 1 |
| p.A59V | LGG | 1 |
| p.R164W | OV | 1 |
| p.E135K | LUSC | 1 |
| p.Q29H | LUSC | 1 |
| p.L25I | SARC | 1 |
| Top |
| TissGeneCNV for CETN1 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for CETN1 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Top |
| TissGeneNet for CETN1 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| CETN1, PRKACA, CCNE1, USP49, TBCCD1 (tumor) | CETN1, PRKACA, CCNE1, USP49, TBCCD1 (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| CETN1, PRKACA, CCNE1, USP49, TBCCD1 (tumor) | CETN1, PRKACA, CCNE1, USP49, TBCCD1 (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| CETN1, PRKACA, CCNE1, USP49, TBCCD1 (tumor) | CETN1, PRKACA, CCNE1, USP49, TBCCD1 (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| CETN1, PRKACA, CCNE1, USP49, TBCCD1 (tumor) | CETN1, PRKACA, CCNE1, USP49, TBCCD1 (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| CETN1, PRKACA, CCNE1, USP49, TBCCD1 (tumor) | CETN1, PRKACA, CCNE1, USP49, TBCCD1 (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| CETN1, PRKACA, CCNE1, USP49, TBCCD1 (tumor) | CETN1, PRKACA, CCNE1, USP49, TBCCD1 (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| CETN1, PRKACA, CCNE1, USP49, TBCCD1 (tumor) | CETN1, PRKACA, CCNE1, USP49, TBCCD1 (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| CETN1, PRKACA, CCNE1, USP49, TBCCD1 (tumor) | CETN1, PRKACA, CCNE1, USP49, TBCCD1 (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| CETN1, PRKACA, CCNE1, USP49, TBCCD1 (tumor) | CETN1, PRKACA, CCNE1, USP49, TBCCD1 (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| CETN1, PRKACA, CCNE1, USP49, TBCCD1 (tumor) | CETN1, PRKACA, CCNE1, USP49, TBCCD1 (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| CETN1, PRKACA, CCNE1, USP49, TBCCD1 (tumor) | CETN1, PRKACA, CCNE1, USP49, TBCCD1 (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| CETN1, PRKACA, CCNE1, USP49, TBCCD1 (tumor) | CETN1, PRKACA, CCNE1, USP49, TBCCD1 (normal) |
 |  |
| Top |
| TissGeneProg for CETN1 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for CETN1 |
| TissGeneDrug for CETN1 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for CETN1 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0027627 | Neoplasm Metastasis | 21 | BeFree |
| umls:C0006142 | Malignant neoplasm of breast | 5 | BeFree |
| umls:C0678222 | Breast Carcinoma | 5 | BeFree |
| umls:C0235974 | Pancreatic carcinoma | 4 | BeFree |
| umls:C0346647 | Malignant neoplasm of pancreas | 4 | BeFree |
| umls:C0024623 | Malignant neoplasm of stomach | 3 | BeFree |
| umls:C0178874 | Tumor Progression | 3 | BeFree |
| umls:C0242379 | Malignant neoplasm of lung | 3 | BeFree |
| umls:C0376358 | Malignant neoplasm of prostate | 3 | BeFree |
| umls:C0596263 | Carcinogenesis | 3 | BeFree |
| umls:C0600139 | Prostate carcinoma | 3 | BeFree |
| umls:C0684249 | Carcinoma of lung | 3 | BeFree |
| umls:C0699791 | Stomach Carcinoma | 3 | BeFree |
| umls:C0005684 | Malignant neoplasm of urinary bladder | 2 | BeFree |
| umls:C0007102 | Malignant tumor of colon | 2 | BeFree |
| umls:C0007134 | Renal Cell Carcinoma | 2 | BeFree |
| umls:C0009402 | Colorectal Carcinoma | 2 | BeFree |
| umls:C0011615 | Dermatitis, Atopic | 2 | BeFree |
| umls:C0025202 | melanoma | 2 | BeFree |
| umls:C0033860 | Psoriasis | 2 | BeFree |
| umls:C0699790 | Colon Carcinoma | 2 | BeFree |
| umls:C0699885 | Carcinoma of bladder | 2 | BeFree |
| umls:C1527249 | Colorectal Cancer | 2 | BeFree |
| umls:C2239176 | Liver carcinoma | 2 | BeFree |
| umls:C0004096 | Asthma | 1 | BeFree |
| umls:C0011603 | Dermatitis | 1 | BeFree |
| umls:C0017601 | Glaucoma | 1 | BeFree |
| umls:C0018213 | Graves Disease | 1 | BeFree |
| umls:C0021053 | Immune System Diseases | 1 | BeFree |
| umls:C0023269 | leiomyosarcoma | 1 | BeFree |
| umls:C0023467 | Leukemia, Myelocytic, Acute | 1 | BeFree |
| umls:C0027121 | Myositis | 1 | BeFree |
| umls:C0030305 | Pancreatitis | 1 | BeFree |
| umls:C0037274 | Dermatologic disorders | 1 | BeFree |
| umls:C0151779 | Cutaneous Melanoma | 1 | BeFree |
| umls:C0155877 | Allergic asthma | 1 | BeFree |
| umls:C0206698 | Cholangiocarcinoma | 1 | BeFree |
| umls:C0268151 | Classical galactosemia | 1 | BeFree |
| umls:C0282606 | Myomatous neoplasm | 1 | BeFree |
| umls:C0333463 | Senile Plaques | 1 | BeFree |
| umls:C0338106 | Adenocarcinoma of colon | 1 | BeFree |
| umls:C0524851 | Neurodegenerative Disorders | 1 | BeFree |
| umls:C0549473 | Thyroid carcinoma | 1 | BeFree |
| umls:C0677898 | invasive cancer | 1 | BeFree |
| umls:C0949664 | Tauopathies | 1 | BeFree |
| umls:C1516170 | Cancer Cell Growth | 1 | BeFree |
| umls:C1631597 | VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1 (disorder) | 1 | BeFree |
| umls:C1832097 | EPIDERMAL DIFFERENTIATION COMPLEX | 1 | BeFree |
| umls:C1868851 | Pulmonary arterial hypertension associated with portal hypertension | 1 | BeFree |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |